rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1
|
pubmed:dateCreated |
2004-12-31
|
pubmed:abstractText |
Genetic (human leukocyte antigen), disease-related and demographic risk factors for nevirapine reactions were examined in a nevirapine-exposed cohort. Cases involving combinations of hepatitis, fever or rash were associated with an interaction between HLA-DRB1*0101 and the percentage of CD4, whereas no associations were detected for isolated rash. These data suggest that HLA-DRB1*0101 and the CD4 status may determine susceptibility to nevirapine hypersensitivity, consistent with a CD4 T-cell-dependent immune response to nevirapine-specific antigens.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0269-9370
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
3
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
97-9
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:15627041-Adult,
pubmed-meshheading:15627041-Cohort Studies,
pubmed-meshheading:15627041-Drug Hypersensitivity,
pubmed-meshheading:15627041-Female,
pubmed-meshheading:15627041-Genetic Predisposition to Disease,
pubmed-meshheading:15627041-HLA Antigens,
pubmed-meshheading:15627041-HLA-A Antigens,
pubmed-meshheading:15627041-HLA-DRB1 Chains,
pubmed-meshheading:15627041-Humans,
pubmed-meshheading:15627041-Immunity, Cellular,
pubmed-meshheading:15627041-Male,
pubmed-meshheading:15627041-Nevirapine,
pubmed-meshheading:15627041-Reverse Transcriptase Inhibitors
|
pubmed:year |
2005
|
pubmed:articleTitle |
Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts.
|
pubmed:affiliation |
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|